Arterial baroreceptor control of blood pressure in man.

G. Mancia,G. Grassi,G. Bertinieri,A. Ferrari,A. Zanchetti

DOI: https://doi.org/10.1016/0165-1838(84)90070-5

1984-09-01

Journal of the Autonomic Nervous System

Abstract:

What problem does this paper attempt to address?

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: an Asian Multiregional, Randomized Study.

Pu Yeong-Shiau,Ahn Hanjong,Han Weiqing,Huang Shu-Pin,Wu Hsi-Chin,Ma Lulin,Yamada Shunsuke,Suga Kazutaka,Xie Li-Ping

DOI: https://doi.org/10.1007/s12325-022-02140-2

2022-01-01

Advances in Therapy

Abstract:Enzalutamide significantly improved clinical outcomes compared with placebo in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) with disease progression despite androgen deprivation therapy (ADT) in the PREVAIL study. However, few patients from Asia were enrolled. Our study (NCT02294461) aimed to evaluate the safety and efficacy of enzalutamide in this disease setting in patients in mainland China, Korea, Taiwan, and Hong Kong. In this double-blind, phase III study, patients with asymptomatic/mildly symptomatic metastatic prostate cancer and disease progression despite ADT were randomized to enzalutamide (160 mg/day) or placebo. The primary endpoint was time to prostate-specific antigen (PSA) progression. Secondary endpoints included overall survival, radiographic progression-free survival, time to first skeletal-related event (SRE), time to initiation of cytotoxic chemotherapy, PSA response ≥ 50%, best overall soft-tissue response, and safety. Pre-planned interim analysis was scheduled following approximately 175 PSA-progression events (67% of targeted total of 261 events). An additional 5-year landmark analysis of overall survival, time to antineoplastic therapy, and safety was performed. The double-blind study period was stopped after interim analysis owing to the benefit of enzalutamide over placebo. Overall, 388 patients were randomized (enzalutamide, n = 198; placebo, n = 190). Baseline characteristics were balanced between treatment groups. Enzalutamide significantly reduced risk of PSA progression vs placebo (hazard ratio 0.38; 95% CI 0.27–0.52; P < 0.0001). Median time to PSA progression was 8.31 months with enzalutamide and 2.86 months with placebo. Secondary endpoints, including 5-year overall survival, were significantly improved with enzalutamide, except time to first SRE. Adverse-event incidence was similar between enzalutamide and placebo. Fatigue was the most common drug-related adverse event in both treatment groups. Enzalutamide significantly reduced risk of PSA progression, improved secondary efficacy endpoints, and was well tolerated in chemotherapy-naïve Asian patients with mCRPC with disease progression despite ADT. www.clinicaltrials.gov NCT02294461.
Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study

Shuhei Hara,Keiichiro Mori,Wataru Fukuokaya,Naoya Tomomasa,Takahiro Oguchi,Yusuke Takahashi,Shun Saito,Jun Katami,Takayuki Sano,Soushi Kadena,Masaki Hashimoto,Yuji Yata,Eriko Nishi,Yushi Suhara,Shigeyoshi Takamizawa,Shiro Kurawaki,Hirotaka Suzuki,Keiichiro Miyajima,Kosuke Iwatani,Fumihiko Urabe,Kagenori Ito,Takafumi Yanagisawa,Shunsuke Tsuzuki,Tatsuya Shimomura,Takahiro Kimura

DOI: https://doi.org/10.1007/s10147-024-02548-6

2024-05-22

International Journal of Clinical Oncology

Abstract:Phase III clinical trials demonstrated the efficacy of enzalutamide and apalutamide in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and PSA doubling time ≤10 months. Although these drugs have been shown to vary in their adverse event (AE) profiles, the differences in their efficacy profiles remain to be evaluated. Therefore, this retrospective study was conducted to evaluate the efficacy of these drugs in patients with nmCRPC.

oncology
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study

Akira Nagahara,Motohide Uemura,Mototaka Sato,Wataru Nakata,Masao Tsujihata,Tetsuya Takao,Soichi Matsumura,Kensaku Nishimura,Shingo Takada,Toshichika Iwanishi,Yasuyuki Kobayashi,Yu Ishizuya,Tsuyoshi Takada,Koichi Okada,Hitoshi Inoue,Taigo Kato,Koji Hatano,Atsunari Kawashima,Takeshi Ujike,Kazutoshi Fujita,Norio Nonomura

DOI: https://doi.org/10.1093/jjco/hyae004

IF: 2.925

2024-02-01

Japanese Journal of Clinical Oncology

Abstract:Abstract Background Alternative anti-androgen therapy has been widely used as a first-line treatment for castration-resistant prostate cancer, and it may affect treatment outcome of subsequent agents targeting the androgen receptor axis. We conducted the prospective observational DELC (Determination of Enzalutamide Long-term safety and efficacy for Castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy) study to evaluate the efficacy of enzalutamide in patients with castration-resistant prostate cancer who underwent prior combined androgen blockade with bicalutamide and then alternative anti-androgen therapy with flutamide. Methods The DELC study enrolled 163 Japanese patients with castration-resistant prostate cancer who underwent alternative anti-androgen therapy with flutamide following failure of initial combined androgen blockade with bicalutamide in multiple institutions between January 2016 and March 2019. Primary endpoint was overall survival. Administration of enzalutamide was started at 160 mg orally once daily in all patients. Results The rate of decline of prostate-specific antigen by 50% or more was 72.2%, and median overall survival was 42.05 months. Multivariate analysis revealed that higher pretreatment serum levels of prostate-specific antigen (≥11.3 ng/mL; P = 0.004), neuron-specific enolase (P = 0.014) and interleukin-6 (≥2.15 pg/mL; P = 0.004) were independent risk factors for overall survival. Fatigue (30.0%), constipation (19.6%) and appetite loss (17.8%) were the most common clinically relevant adverse events. The enzalutamide dose was not reduced in any patient under the age of 70, but adherence was decreased in those over 70. Conclusions In the DELC study, the safety of enzalutamide was comparable to that in previous reports. Serum levels of neuron-specific enolase and interleukin-6 were suggested as prognostic factors for castration-resistant prostate cancer with potential clinical utility.

oncology
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa

Koji Mita,Kouji Izumi,Akihiro Goriki,Ryo Tasaka,Tomoya Hatayama,Takashi Shima,Yuki Kato,Manabu Kamiyama,Shogo Inoue,Nobumichi Tanaka,Seiji Hoshi,Takehiko Okamura,Yuko Yoshio,Hideki Enokida,Ippei Chikazawa,Noriyasu Kawai,Kohei Hashimoto,Takashi Fukagai,Kazuyoshi Shigehara,Shizuko Takahara,Yoshifumi Kadono,Atsushi Mizokami

DOI: https://doi.org/10.3390/cancers16030508

2024-01-25

Cancers

Abstract:Enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) can improve the survival of patients with castration-resistant prostate cancer (CRPC). However, the agent that is more effective against nonmetastatic CRPC remains unclear. To evaluate the agent that can be used as the first-line treatment for CRPC, an investigator-initiated, multicenter, randomized controlled trial (ENABLE Study for PCa) including both metastatic and nonmetastatic CRPC was conducted in Japan. The prostate-specific antigen (PSA) response rate, overall survival, some essential survival endpoints, and safety of patients with nonmetastatic CRPC were also analyzed. In this subanalysis, 15 and 26 patients in the ENZ and ABI arms, respectively, presented with nonmetastatic CRPC. There was no significant difference in terms of the PSA response rate between the ENZ and ABI arms (80% and 64%, respectively; p = 0.3048). The overall survival did not significantly differ between the two arms (HR: 0.68; 95% CI: 0.22–2.14, p = 0.5260). No significant differences were observed in terms of radiographic progression-free survival and cancer-specific survival between the ENZ and ABI arms (HR: 0.81; 95% CI: 0.35–1.84; p = 0.6056 and HR: 0.72; 95% CI: 0.19–2.73; p = 0.6443, respectively). Only four and six patients in the ENZ and ABI arms, respectively, had ≥grade 3 adverse events. ABI and ENZ had similar efficacy and safety profiles in patients with nonmetastatic CRPC.

oncology
Electron beam ion sources and traps (invited)

R. Becker

DOI: https://doi.org/10.1063/1.1150302

2000-02-04

Abstract:The electron beam method of stepwise ionization to highest charge states has found applications in electron beam ion sources (EBISs) for accelerators and atomic physics collision experiments as well as in electron beam ion traps (EBITs) for x-ray and mass spectroscopy. A dense and almost monoenergetic electron beam provides a unique tool for ionization, because radiative recombination by slow electrons is negligible and charge exchange is almost avoided in ultrahigh vacua. These are essential differences to electron cyclotron resonance ion sources with inevitable low energy electrons and comparatively high gas pressure. The distinction between EBIS and EBIT as genuine devices has become meaningless, because EBISs may work as traps and almost all EBITs are feeding beamlines for external experiments. More interesting is to note the diversification of these devices, which demonstrates that a matured technology is finding dedicated answers for different applications. At present we may distinguish six major li...
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

Tomohiro Tsuchiya,Keiichiro Imanaka,Yuki Iwaki,Ryo Oyama,Katsuyoshi Hashine,Akito Yamaguchi,Hiroji Uemura

DOI: https://doi.org/10.1007/s10147-019-01526-7

2019-08-24

International Journal of Clinical Oncology

Abstract:BackgroundApalutamide, a nonsteroidal potent androgen receptor antagonist, was safe and effective in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic-CRPC (mCRPC) in global studies. In this phase 1 study, safety, pharmacokinetics (PK), and efficacy of apalutamide were evaluated in Japanese patients with mCRPC.MethodsIn this open-label, multi-center study, patients received apalutamide 240 mg (once-daily, orally) for first 1 week (PK week) during which PK parameters were assessed. 1 week later (Cycle 1 Day1), after reassessing safety, continuous daily dosing (4 weeks/cycle; once-daily orally) was initiated. Endpoints evaluated were: safety, tolerability, PK and antitumour efficacy of apalutamide. Dose-limiting toxicities (DLTs) were evaluated during PK week and Cycle 1.ResultsAll six patients received apalutamide. The most common treatment-emergent adverse events (TEAEs) were abdominal discomfort, nasopharyngitis, dysgeusia, rash, and hot flush [2/6 patients (33.3%) each]. No death or DLTs were reported. Grade 3 TEAEs were spinal-cord compression and renal disorder (1/6 patient each). In continuous daily dosing period, PK steady-state of apalutamide was reached approximately by week 4. A significant accumulation of apalutamide was observed (mean accumulation index 3.55), based on AUC0–24. Median (range) serum prostate-specific antigen level decreased from 54.42 (8.92–310.11) ng/mL at baseline to 11.70 (0.37–47.74) ng/mL at week 12 with ≥ 50% reduction in 4/6 (66.7%) patients and 90% reduction in 2/6 (33.3%) patients.ConclusionApalutamide had manageable safety profile, without any DLT or any new safety signals, and favourable efficacy in Japanese mCRPC patients. Thus, it was ascertained to be an adequate dosage regimen in Japanese mCRPC patients.Trial registrationClinicalTrials.gov identifier: NCT02162836.

oncology
Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Choung Soo Kim,Young Deuk Choi,Sang Eun Lee,Hyun Moo Lee,Takeshi Ueda,Junji Yonese,Takashi Fukagai,Edmund Chiong,Weber Lau,Sarang Abhyankar,Ad Theeuwes,Bertrand Tombal,Tomasz M. Beer,Go Kimura

DOI: https://doi.org/10.1097/md.0000000000007223

IF: 1.6

2017-07-01

Medicine

Abstract:BACKGROUND: Enzalutamide is an androgen receptor (AR) inhibitor that acts on different steps in the AR signaling pathway. In PREVAIL, an international, phase III, double-blind, placebo-controlled trial, enzalutamide significantly reduced the risk of radiographic progression by 81% (hazard ratio [HR], 0.19; P < .0001) and reduced the risk of death by 29% (HR, 0.71; P < .0001) compared with placebo in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.METHODS: To evaluate treatment effects, safety, and pharmacokinetics of enzalutamide in East Asian patients from the PREVAIL trial, we performed a post hoc analysis of the Japanese, Korean, and Singaporean patients. PREVAIL enrolled patients with asymptomatic or mildly symptomatic chemotherapy-naïve metastatic castration-resistant prostate cancer who had progressed on androgen deprivation therapy. During the study, patients received enzalutamide (160 mg/d) or placebo (1:1) until death or discontinuation because of radiographic progression or skeletal-related event and initiation of subsequent therapy. Centrally assessed radiographic progression-free survival (rPFS) and overall survival (OS) were coprimary endpoints. The secondary endpoints of the PREVAIL trial were investigator-assessed rPFS, time to initiation of chemotherapy, time to prostate-specific antigen (PSA) progression, and PSA response (≥50% decline).RESULTS: Of 1717 patients, 148 patients were enrolled at sites in East Asia (enzalutamide 73, placebo 75). Treatment effect of enzalutamide versus placebo was consistent with that for the overall population as indicated by the HRs (95% confidence interval) of 0.38 (0.10-1.44) for centrally assessed rPFS, 0.59 (0.29-1.23) for OS, 0.33 (0.19-0.60) for time to chemotherapy, and 0.32 (0.20-0.50) for time to PSA progression. In East Asian patients, PSA responses were observed in 68.5% and 14.7% of enzalutamide- and placebo-treated patients, respectively. The enzalutamide plasma concentration ratio (East Asian:non-Asian patients) was 1.12 (90% confidence interval, 1.05-1.20) at 13 weeks. Treatment-related adverse events grade ≥ 3 occurred in 1.4% and 2.7% of enzalutamide- and placebo-treated East Asian patients, respectively.CONCLUSIONS: Treatment effects and safety of enzalutamide in East Asian patients were generally consistent with those observed in the overall study population from PREVAIL. CLINICALTRIALS.GOV NUMBER: NCT01212991.

medicine, general & internal
Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study

D. Ye,H. Ahn,Y-S. Pu,H. Weiqing,L-P. Xie,S-P. Huang,H-C. Wu,L. Ma,S. Yamada,S. Noda,Y. Sun

DOI: https://doi.org/10.1093/annonc/mdw372.33

IF: 51.769

2016-01-01

Annals of Oncology

Abstract:In PREVAIL, pts with progressive mCRPC following ADT had significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) on ENZ vs PL (Beer TM et al, N Engl J MED, 2014). In the current study, the efficacy and safety of ENZ vs PL were evaluated in a similar patient population in China, Taiwan, Hong Kong and South Korea. Pts with asymptomatic/mildly symptomatic progressive mCRPC following ADT were randomised 1:1 to ENZ (160 mg/day) or PL. The primary endpoint was time to prostate-specific antigen (PSA) progression (time from randomisation to PSA progression or death). The secondary endpoints were OS (time from randomisation to death) and rPFS (time from randomisation to radiographic progression). An interim analysis was planned following 169 PSA progression events. The unstratified Cox proportional hazards model (covariate = treatment group) and log-rank test (2-sided significance level = 0.011, primary; 0.05, secondary) were used. Safety was assessed by recording adverse events (AE). 409 pts from 49 centres were randomised (209 ENZ, 200 PL). Baseline characteristics were balanced between treatment groups. 169 PSA progression events occurred. Median time to PSA progression was 7.5 months in the ENZ arm vs 2.9 for PL (HR 0.36; 95% CI 0.27, 0.50; p < 0.0001). Median OS was not yet reached (NYR). Current results show a reduced risk of death in the ENZ arm vs PL (HR 0.35; 95% CI 0.17, 0.70; p = 0.0021). Median time to radiographic progression was also NYR for ENZ but was 4.7 months for PL (HR 0.28; 95% CI 0.19, 0.42; p < 0.0001). The median time on treatment was 6.6 months for ENZ and 3.7 for PL. Although slightly more ENZ pts reported at least 1 treatment-emergent AE (TEAE; 84.7% vs 80.5%), more pts in the PL arm reported at least 1 serious TEAE, 17.2% vs 24.5%; grade ≥3 TEAE, 24.4% vs 29.5% and TEAE leading to treatment discontinuation, 12.9% vs 17.0%. No seizures or convulsions were reported in either arm. ENZ showed significantly improved time to PSA progression over PL and was generally well tolerated. The trial was stopped as it had reached its primary objective.
Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy

Ryo Fujiwara,Shinya Yamamoto,Kosuke Takemura,Takeshi Yuasa,Noboru Numao,Tomohiko Oguchi,Yosuke Yasuda,Yusuke Yoneoka,Junji Yonese

DOI: https://doi.org/10.3390/cancers16152659

2024-07-27

Cancers

Abstract:We conducted a retrospective evaluation of the clinical outcomes and prognostic factors in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with first-line androgen receptor signaling inhibitors (ARSI) in real-world clinical practice in Japan. Between 2012 and 2023, a total of 127 consecutive patients with nmCRPC received ARSI treatment. Overall survival (OS), metastatic-free survival (MFS), and prostate-specific antigen–progression-free survival (PSA–PFS) from ARSI initiation were assessed using the Kaplan–Meier methodology. Clinical factors associated with OS in nmCRPC were analyzed using the Cox proportional hazards model. Among the patients, 72, 26, 12, and 17 received enzalutamide (ENZ), abiraterone (ABI), apalutamide (APA), and darolutamide (DARO) as first-line therapy. The median OS and MFS for all patients were 79.0 and 42.0 months, respectively. Median PSA–PFS was 27.0, 20.0, 10.0, and 14.0 months for patients treated with ENZ, ABI, APA, and DARO, respectively (p = 0.33). Multivariate analysis revealed that a baseline PSA level ≥ 3.67 ng/mL at ARSI initiation was significantly associated with poorer OS (p = 0.002). ARSI demonstrated favorable efficacy in nmCRPC patients. There were no significant differences in clinical outcomes among different types of ARSI therapy for nmCRP. Elevated baseline PSA at ARSI initiation was significantly associated with poorer OS.

oncology
Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Scott T. Tagawa,Krishnan Ramaswamy,Ahong Huang,Jack Mardekian,Neil M. Schultz,Li Wang,Rickard Sandin,Stanislav Lechpammer,Daniel J. George

DOI: https://doi.org/10.1038/s41391-021-00318-3

2021-02-21

Prostate Cancer and Prostatic Diseases

Abstract:Abstract Objective Evaluation of the comparative effectiveness of enzalutamide and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) is limited to meta-analyses of randomized trials that exclude patients with significant comorbidities. We evaluated overall survival (OS) in patients with chemotherapy-naive mCRPC treated with enzalutamide or abiraterone acetate (abiraterone) in a real-world single payer setting. Methods A retrospective analysis (4/1/2014–3/31/2018) of the Veterans Health Administration (VHA) database was conducted. Patients with mCRPC had ≥1 pharmacy claim for enzalutamide or abiraterone (first claim date = index date) following disease progression on surgical/medical castration, without chemotherapy <12 months prior to index date. Patients had continuous VHA enrollment for ≥12 months pre-index date and were followed until death, disenrollment, or end of study. Kaplan–Meier analysis and multivariable Cox proportional hazards regression models examined the OS treatment effect. Results Patients with chemotherapy-naive mCRPC ( N = 3174; enzalutamide, n = 1229; abiraterone, n = 1945) had mean ages of 74 and 73 years, respectively. Median follow-up was 18.27 and 19.07 months with enzalutamide and abiraterone, respectively. Enzalutamide-treated patients had longer median treatment duration than abiraterone-treated patients (9.93 vs 8.47 months, respectively, p = 0.0008). After baseline comorbidity adjustment, enzalutamide-treated patients had a 16% reduced risk of death (hazard ratio [HR] = 0.84; 95% CI, 0.76–0.94; p = 0.0012). For patients who remained on first line-therapy only, enzalutamide-treated patients had improved OS versus abiraterone-treated patients (HR = 0.71; 95% CI, 0.62–0.82). Enzalutamide-treated patients who crossed over to abiraterone had a comparable risk of death versus abiraterone-treated patients who crossed over to enzalutamide (HR = 1.10; 95% CI, 0.89–1.35). These results were confirmed by sensitivity analysis, which considered prognostic variables. Conclusions Retrospective analysis of the VHA database indicated that chemotherapy-naive patients with mCRPC initiating therapy with enzalutamide had improved survival versus abiraterone.

oncology,urology & nephrology
Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

ZhenHeng Wei,ChuXin Chen,BoWen Li,YongYue Li,Hong Gu

DOI: https://doi.org/10.3389/fonc.2021.732599

IF: 4.7

2021-08-27

Frontiers in Oncology

Abstract:Objective The androgen receptor-targeting drugs abiraterone acetate and enzalutamide have shown positive results as treatments for metastatic castration-resistant prostate cancer (mCRPC). Therefore, a meta-analysis was conducted to compare the efficacy and safety of abiraterone acetate and enzalutamide in patients with mCRPC. Methods We retrieved relevant articles from PubMed, Cochrane, and EMBASE published before December 31, 2020. Eleven articles were initially selected, and four phase III, double-blind, randomized controlled trials of abiraterone acetate and enzalutamide that involved 5199 patients with mCRPC were included. The end points were time to prostate-specific antigen progression (TTPP), according to the prostate-specific antigen working group criteria; overall survival (OS); and radiographic progression-free survival (rPFS). Results Four randomized, controlled clinical trials involving 5199 patients were included in this study. The results of the meta-analysis showed that compared with placebo alone, abiraterone significantly improved OS (HR=0.69, 95% CI: 0.60-0.8, P<0.00001), rPFS (HR=0.64, 95% CI: 0.57-0.71, P < 0.00001), and TTPP (HR=0.52, 95% CI: 0.45-0.59, P < 0.00001) in patients with mCRPC. Compared with placebo, enzalutamide significantly improved OS (HR=0.67, 95% CI: 0.59-0.75, P<0.00001), rPFS (HR=0.33, 95% CI: 0.29-0.37, P< 0.00001), and TTPP (HR=0.19, 95% CI: 0.17-0.22, P < 0.00001). An indirect comparison was performed to compare the efficacy of abiraterone and enzalutamide. The results showed that there was no significant difference between abiraterone and enzalutamide with regard to improving the OS of patients with mCRPC (HR=1.03, 95% CI: 0.854-1.242). Enzalutamide was superior to abiraterone with regard to improving rPFS in patients with mCRPC (HR=0.516, 95% CI: 0.438-0.608). With regard to improving TTPP, the efficacy of enzalutamide was better than that of abiraterone (HR=0.365, 95% CI: 0.303-0.441). In sAE, there was no difference between abiraterone and enzalutamide (P=0.21, I 2 = 38%). Conclusions Compared with placebo, both abiraterone and enzalutamide significantly prolonged OS, rPFS, and TTPP in patients with mCRPC. There was no difference in safety between abiraterone and enzalutamide. In addition, enzalutamide had better efficacy than abiraterone with regard to improving rPFS and TTPP but not OS, but the level of evidence was low. Therefore, a large direct comparison trial is needed to compare the efficacy of the two drugs. Systematic Review Registration PROSPERO, identifier (CRD42021226808)

oncology
Real‐world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

Takuya Tsujino,Satoshi Tokushige,Kazumasa Komura,Wataru Fukuokaya,Takahiro Adachi,Yosuke Hirasawa,Takeshi Hashimoto,Atsuhiko Yoshizawa,Masanobu Saruta,Takaya Ohno,Keita Nakamori,Ryoichi Maenosono,Kazuki Nishimura,Shogo Yamazaki,Taizo Uchimoto,Takafumi Yanagisawa,Keiichiro Mori,Fumihiko Urabe,Shunsuke Tsuzuki,Kosuke Iwatani,Shutaro Yamamoto,Kiyoshi Takahara,Teruo Inamoto,Takahiro Kimura,Yoshio Ohno,Ryoichi Shiroki,Haruhito Azuma

DOI: https://doi.org/10.1002/cam4.6536

IF: 4.711

2023-09-16

Cancer Medicine

Abstract:In the daily clinic, ARSIs, including AA plus prednisone, are offered to a different patient population from randomized controlled trials as the elder and more comorbidities exist. Whether AA plus prednisone for nmCRPC elicits benefits on OS has not been fully proven. We report the real‐world survival outcomes comparing AA plus prednisone and Enz for nmCRPC and revealed that non‐cancer‐caused death might increase for patients treated with AA plus prednisone compared to Enz. Background There is little evidence of abiraterone acetate (AA) plus prednisone for patients with non‐metastatic castration‐resistant prostate cancer (nmCRPC). In this study, we conducted a comparative analysis of real‐world survival outcomes between AA plus prednisone and enzalutamide (Enz) in patients with nmCRPC, utilizing our consortium dataset. Materials and Methods The clinical records of 133 nmCRPC patients treated with first‐line Enz or AA plus prednisone were analyzed. The primary endpoints of the study were overall survival (OS) and cancer‐specific survival (CSS). Cumulative incidence function (CIF) using Fine and Gray models was also utilized to assess non‐cancer‐caused death considering the competing risk of cancer‐caused death. Results During a median follow‐up of 36 months, 34 patients (25.6%) had deceased, with a median OS of 99 months in the entire cohort. There were no significant differences in comorbidities between the Enz and AA groups. Time to PSA progression (TTPP: HR 0.81, 95% CI 0.51–1.30, P = 0.375) and CSS (HR 1.32, 95% CI 0.55–3.44, P = 0.5141) were comparable between the two groups. However, intriguingly, there was a trend towards shorter OS in patients treated with AA plus prednisone compared to Enz (HR 0.57, 95% CI 0.29–1.12, P = 0.0978, median of 99 and 69 months in Enz and AA groups, respectively). CIF analysis revealed that nmCRPC patients treated with AA plus prednisone were more likely to result in non‐cancer‐caused death than those treated with Enz (HR 5.22, 95% CI 1.88–14.50, P = 0.0014). Conclusions Our real‐world survival analysis suggests that while AA plus prednisone may demonstrate comparable treatment efficacy to Enz in the context of nmCRPC, there may be an increased risk of non‐cancer‐caused death. Physicians should take into consideration this information when making treatment decisions for patients with nmCRPC.

oncology
Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa

Nobumichi Tanaka,Kouji Izumi,Yasushi Nakai,Takashi Shima,Yuki Kato,Koji Mita,Manabu Kamiyama,Shogo Inoue,Seiji Hoshi,Takehiko Okamura,Yuko Yoshio,Hideki Enokida,Ippei Chikazawa,Noriyasu Kawai,Kohei Hashimoto,Takashi Fukagai,Kazuyoshi Shigehara,Shizuko Takahara,Atsushi Mizokami

DOI: https://doi.org/10.1002/pros.24796

2024-09-21

The Prostate

Abstract:Background A head‐to‐head comparison between enzalutamide (ENZ) and abiraterone plus prednisolone (ABI) revealed similar survival benefits for castration‐resistant prostate cancer (CRPC) in the ENABLE study for PCa. Considering that a dose reduction of ENZ and ABI has demonstrated sufficient inhibitory ability of androgen receptor (AR) signaling, we analyzed the efficacy of modified doses of these agents in the ENABLE study for PCa. Methods This investigator‐initiated, multicenter, randomized controlled trial that was conducted in Japan analyzed the prespecified survival endpoints, prostate‐specific antigen (PSA) response rate ( ≥50% decline from baseline), and safety profile in patients treated with modified doses (ENZ ≤ 120 mg/day, ABI ≤ 750 mg/day) compared with those treated with a standard dose (ENZ 160 mg/day, ABI 1000 mg/day) as a starting dose. Results In total, 92 patients in each arm were treated and analyzed; 16 patients were treated with a modified dose in both the ENZ and ABI arms, respectively. Moreover, 32 patients treated with modified doses showed a significantly better time to PSA progression (TTPP) and overall survival (OS) compared with the 152 patients treated with a standard dose (HR 0.47, 95%CI 0.27–0.83, p = 0.0379, and HR 0.35, 95%CI 0.19–0.63, p = 0.0162). Despite a significantly longer TTPP in the modified ABI group than in the standard ABI group (HR 0.29, 95%CI 0.14–0.62, p = 0.0248), no significant difference was observed in the TTPP between the modified and standard ENZ groups (p = 0.5366). Furthermore, similar adverse event rates and grades were observed in each treatment dose group. Conclusions The modified doses of ABI showed better TTPP than the standard dose of ABI and may be a potential treatment option for CRPC patients; however, its mechanism is still unclear, although its ability to suppress AR signaling is equivalent to that of a standard dose.

endocrinology & metabolism,urology & nephrology
A study of the association between enzalutamide blood concentrations and adverse events in patients with castration-resistant prostate cancer.

Taro Iguchi,MInoru Kato,Yukiyoshi Hirayama,Takeshi Yamasaki,Sayaka Yasuda,Nobuyo Morita,Ippei Chikazawa,Wakaba Fukushima,Satoshi Tamada,Katsuhito Miyazawa

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.102

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:102 Background: Enzalutamide (ENZA) is effective in castration-resistant prostate cancer (CRPC), but subjective adverse events (AEs) such as fatigue and decreased appetite may make it difficult to continue ENZA due to AEs despite its effectiveness. Owing to AEs, half of the patients required a dose reduction to 120 mg, thereby eliminating the AEs and enabling patients to continue taking ENZA. We hypothesized that a dose reduction to 120 mg of ENZA would reduce AEs in patients while keeping serum concentrations in the therapeutic range. Methods: Patients with CRPC were treated with ENZA from 2015 to 2020 at Osaka City University Hospital and their serum was stored at least twice with written consent. All patients were treated with an initial dose of 160 mg of ENZA, and the dose was reduced to 120 mg if they complained of AEs. In the full dose group (no AEs with 160 mg of ENZA), serum concentrations of ENZA and its active metabolite (N-desmethyl enzalutamide: M2) were measured at 1, 3, and 6 months. In the reduced dose group, serum concentrations were measured before and after dose reduction. To clarify the relationship between AEs and the serum ENZA and M2 concentrations, the serum ENZA and M2 concentrations in patients with/without AEs and before/after dose reduction were compared. To examine whether dose reductions affect the efficacy of ENZA, PSA progression free survival, and the overall survival were compared between the full dose group and the reduced dose group. Results: Serum ENZA and M2 concentrations were measured in 246 samples from 84 patients and mean effective serum concentrations of ENZA + M2 were 28.0, 30.4, and 29.2 μg/mL in the full dose group at 1, 3, and 6 months, respectively; and 29.1 and 24.1 μg/mL at a dose of 160 mg and 120 mg, respectively, in the reduced dose group. Most of AEs were resolved by dose reduction and there was no statistically significant difference in PSA progression free survival (HR: 0.86, 95% CI: 0.44-1.68) or overall survival (HR: 0.60, 95% CI: 0.26-1.40) between the full dose group and the reduced dose group. Conclusions: A correlation between the ENZA dose and serum ENZA + M2 concentration was observed, but no association between AE and serum ENZA or M2 concentration was observed. Dose reduction to 120 mg reduced serum ENZA and M2 concentrations of the patients with AEs and resolved the AEs but did not affect the efficacy of ENZA. These results suggest that patients with AEs at 160 mg of ENZA can have their AEs resolved by reducing the dose to 120 mg without loss of efficacy.

oncology
Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?

Emilio Francesco Giunta,Lorenzo Gasperoni,Ugo De Giorgi

DOI: https://doi.org/10.2217/fon-2023-1019

2024-02-08

Future Oncology

Abstract:Keywords: androgen deprivation therapy castration enzalutamide patient-reported outcomes prostate cancer safety References 1. Van den Broeck T, van den Bergh RCN, Briers E et al. Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations . Eur. Urol. Focus 6(2), 231–234 ( 2020 ).Medline Google Scholar 2. Freedland SJ, De Giorgi U, Gleave M et al. A Phase III randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design . BMJ Open. 11(8), e046588 ( 2021 ).Medline Google Scholar 3. Freedland SJ, de Almeida Luz M, De Giorgi U et al. Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer . N. Engl. J. Med. 389(16), 1453–1465 ( 2023 ).Medline CAS Google Scholar 4. https://www.drugs.com/history/xtandi.html (accessed on 5th November 2023). Google Scholar 5. Scher HI, Fizazi K, Saad F et al. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy . N. Engl. J. Med. 367(13), 1187–1197 ( 2012 ).Medline CAS Google Scholar 6. Payne H, Robinson A, Rappe B et al. European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE . Int. J. Cancer 150(5), 837–846 ( 2022 ).Medline CAS Google Scholar 7. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer . N. Engl. J. Med. 381(2), 121–131 ( 2019 ).Medline CAS Google Scholar 8. Sternberg CN, Fizazi K, Saad F et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer . N. Engl. J. Med. 382(23), 2197–2206 ( 2020 ).Medline CAS Google Scholar 9. Freedland SJ, Gleave M, De Giorgi U et al. Enzalutamide and Quality of Life in Biochemically Recurre -Abstract Truncated-

oncology
Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Bridging Study

Yinghao Sun,Qing Zou,Zhongquan Sun,Changling Li,Chuanjun Du,Zhiwen Chen,Yuxi Shan,Yiran Huang,Jie Jin,Zhang Qun Ye,Liping Xie,Guowen Lin,Yi Feng,Peter De Porre,Weiping Liu,Dingwei Ye

DOI: https://doi.org/10.1111/iju.13051

2016-01-01

International Journal of Urology

Abstract:Objectives: To evaluate the efficacy and safety of abiraterone acetate-prednisone versus placebo-prednisone in Asian metastatic castration-resistant prostate cancer patients who have failed docetaxel-based chemotherapy. Methods: In this double-blind, phase 3 study from China, 214 patients were randomized (2:1) to abiraterone acetate 1000 mg once daily plus prednisone 5 mg twice daily and placebo plus prednisone 5 mg twice daily in 28-day treatment cycles. Results: Abiraterone acetate-prednisone treatment significantly decreased prostate-specific antigen progression risk by 49%, with longer median time to prostate-specific antigen progression of 5.55 months versus 2.76 months in the placebo-prednisone group (hazard ratio 0.506, P = 0.0001, primary end-point). There was a strong trend for improved overall survival in the abiraterone acetate-prednisone group, with a 40% decrease in the risk of death (hazard ratio 0.604, P = 0.0597); however, median survival was not reached in either group because of the short follow-up period (12.9 months) and limited number of observed death events. The prostate-specific antigen response rate was higher in the abiraterone-prednisone group (49.7%) than in the placebo-prednisone group (14.1%). A total of 37.1% patients in this group had pain progression events compared with 50.7% in the placebo-prednisone group. Abiraterone-prednisone significantly decreased the risk of pain progression by 50% (hazard ratio 0.496, P = 0.0014). The incidence of adverse events was similar between the two groups; the most common adverse events being anemia (25.9% for abiraterone-prednisone vs 22.5% for placebo-prednisone), hypokalemia (25.9% and 11.3%), bone pain (23.8% and 21.1%), hypertension (16.1% and 12.7%) and increased aspartate aminotransferase (14.7% and 15.5%), respectively. Conclusions: Abiraterone-prednisone significantly delays disease and pain progression, and prostate-specific antigen, with a favorable benefit-risk ratio in Asian metastatic castration-resistant prostate cancer patients in the post-docetaxel setting.
Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

Pei-Yu Li,Ying-Hao Lu,Chung-Yu Chen

DOI: https://doi.org/10.3389/fonc.2022.822375

IF: 4.7

2022-03-07

Frontiers in Oncology

Abstract:Background Abiraterone and enzalutamide are widely used as first-line treatment for metastatic castration-resistant prostate cancer (mCRPC); however, their efficacy in mCRPC has been inconsistently demonstrated in other outcome studies from real-world databases. The aim of our study was to assess the comparative effectiveness of abiraterone and enzalutamide in patients with mCRPC using real-world data from Taiwan. Methods This retrospective cohort population-based study included patients identified in the Taiwan National Health Insurance Research Database who had been diagnosed with mCRPC and who had taken abiraterone or enzalutamide between December 2014 and August 2017. The study’s outcome evaluated the differences in overall survival (OS) and time to treatment failure (TTF) between abiraterone and enzalutamide over a 15-month follow-up period. The patients were followed from the index date to when the outcome occurred, to December 31, 2018, or to the patients’ withdrawal from the National Health Insurance program. The estimated relative treatment effects of abiraterone and enzalutamide on OS and TTF were adjusted by the inverse probability of treatment weighting (IPTW) using the Kaplan–Meier method and a Cox proportional hazards model. Results The abiraterone and enzalutamide groups consisted of 1,046 and 118 patients, respectively. After IPTW adjustment, 1,164 patients in the abiraterone group and 1,158 in the enzalutamide group underwent an outcome evaluation. Enzalutamide showed a similar OS rate to that of abiraterone (57.58% vs. 49.51%, p = 0.095 by log-rank test). Enzalutamide significantly reduced the risk of death for mCRPC when compared with abiraterone [adjusted hazard ratio (aHR), 0.828; 95% CI 0.731–0.938]. However, similar results were not observed in the TTF outcomes (63.84% vs. 67.79%, p = 0.2651 by log-rank test; aHR, 0.902; 95% CI 0.812–1.002). Conclusion In conclusion, enzalutamide was associated with better OS for mCRPC than abiraterone in the Taiwan population. Our study showed that there was no statistically significant difference in TTF between enzalutamide and abiraterone. Studies with longer surveillance of enzalutamide and abiraterone using real-world databases are needed.

oncology
A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.

Xin Gao,Matthew Raymond Smith,Howard I. Scher,Frank Verholen,Patrick Adorjan,Manjari Dissanayake,Andrew Leonard Laccetti

DOI: https://doi.org/10.1200/jco.2023.41.16_suppl.tps5111

IF: 45.3

2023-06-01

Journal of Clinical Oncology

Abstract:TPS5111 Background: Darolutamide is a structurally distinct and highly potent androgen receptor inhibitor with low blood–brain barrier penetration. In the phase 3 ARAMIS study (NCT02200614) of patients with nonmetastatic castration-resistant prostate cancer, treatment with darolutamide significantly improved metastasis-free survival and overall survival versus placebo, with a favorable safety profile. The incidences of central nervous system adverse events (AEs; e.g. falls, memory impairment, and depression) showed a ≤2% difference between the darolutamide and placebo groups. Fatigue was the only AE with an incidence of > 10% for darolutamide (13.2% vs 8.3% for placebo). In a separate neuroimaging study of healthy volunteers, cerebral blood flow was not altered in patients treated with darolutamide but was significantly reduced in brain areas related to cognition in patients treated with enzalutamide. Furthermore, it is postulated that the low blood–brain barrier penetration of darolutamide may result in lower serum testosterone elevations than those seen with enzalutamide, with the potential of leading to fewer associated feminizing AEs. The objective of ARAMON (NCT05526248) is to compare the effect of darolutamide and enzalutamide monotherapy on post-treatment testosterone levels in patients with hormone-naive prostate cancer experiencing biochemical recurrence after definitive treatment for localized disease. Methods: ARAMON is a two-stage, open-label, phase 2 study of patients with histologically or cytologically confirmed adenocarcinoma of the prostate who have biochemical recurrence after radical primary prostatectomy or radiation therapy, with a prostate-specific antigen (PSA) doubling time of ≤20 months, baseline serum testosterone > 150 ng/dL, and Eastern Cooperative Oncology Group performance status 0/1. During a 52-week lead-in phase, 25 patients will receive darolutamide 600 mg twice daily. If criteria based on serum testosterone increase from baseline to Week 12 are met, the study will proceed to a 52-week randomized phase in which the effects of darolutamide (600 mg twice daily, n = 20) will be compared with the effects of enzalutamide (160 mg once daily, n = 20). The primary endpoint of both phases is the change in serum testosterone level from baseline to Week 12. Secondary endpoints of the randomized phase include the change in serum testosterone levels from baseline to Weeks 24 and 52; PSA at Weeks 4, 12, 24, 36, and 52; changes in blood levels of markers for glucose, lipid metabolism, and endocrine function related to sex hormones; safety; and quality of life. Safety will be assessed through AE monitoring. The first of the 25 planned patients in the lead-in phase was enrolled on January 13, 2023. Clinical trial information: NCT05526248 .

oncology
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Andrew J Armstrong,Arun A Azad,Taro Iguchi,Russell Z Szmulewitz,Daniel P Petrylak,Jeffrey Holzbeierlein,Arnauld Villers,Antonio Alcaraz,Boris Alekseev,Neal D Shore,Francisco Gomez-Veiga,Brad Rosbrook,Fabian Zohren,Shunsuke Yamada,Gabriel P Haas,Arnulf Stenzl

DOI: https://doi.org/10.1200/JCO.22.00193

2022-05-20

Abstract:Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In primary analysis, enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC); however, overall survival data were immature. In the phase III, double-blind, global ARCHES trial (ClinicalTrials.gov identifier: NCT02677896), 1,150 patients with mHSPC were randomly assigned 1:1 to enzalutamide (160 mg once daily) plus ADT or placebo plus ADT, stratified by disease volume and prior docetaxel use. Here, we report the final prespecified analysis of overall survival (key secondary end point) and an update on rPFS, other secondary end points, and safety. After unblinding, 180 (31.3%) progression-free patients randomly assigned to placebo plus ADT crossed over to open-label enzalutamide plus ADT. As of May 28, 2021 (median follow-up, 44.6 months), 154 of 574 patients randomly assigned to enzalutamide plus ADT and 202 of 576 patients randomly assigned to placebo plus ADT had died. Enzalutamide plus ADT reduced risk of death by 34% versus placebo plus ADT (median not reached in either group; hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P < .001). Enzalutamide plus ADT continued to improve rPFS and other secondary end points. Adverse events were generally consistent with previous reports of long-term enzalutamide use. In conclusion, enzalutamide plus ADT significantly prolongs survival versus placebo plus ADT in patients with mHSPC.
The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide

So Nakamura,Masayoshi Nagata,Naoya Nagaya,Takeshi Ashizawa,Hisashi Hirano,Yan Lu,Hisamitsu Ide,Shigeo Horie

DOI: https://doi.org/10.3390/cancers16040772

2024-02-14

Cancers

Abstract:Enzalutamide is a second-generation androgen receptor inhibitor that increases overall survival (OS) rates in patients with metastatic castration-resistant prostate cancer (mCRPC). This study evaluates the efficacy of circulating tumor cell (CTC) status as a prognostic biomarker following enzalutamide administration. A retrospective subgroup analysis and prognostic survey were conducted on 43 patients with mCRPC and bone metastases treated in Juntendo University-affiliated hospitals from 2015 to 2022. Patients were treated with 160 mg enzalutamide daily. CTC analyses on blood samples were performed regularly before and every three months after treatment. The relationship between the patients' clinical factors and the OS rate was analyzed using the log-rank test; the median OS was 37 months. Patients with no detected CTCs at baseline showed significantly longer OS than those with detectable CTCs at baseline. Furthermore, patients demonstrating negative reversion of CTCs during enzalutamide treatment had significantly longer OS than patients with CTC-positivity. Two biomarkers—higher hemoglobin at baseline and achieving negative reversion of CTCs—were significantly associated with prolonged OS. This study suggests that patients achieving CTC-negative reversion during treatment for mCRPC with bone metastases exhibit improved long-term OS. Chronological measurement of CTC status might be clinically useful in the treatment of mCRPC.

oncology

Arterial baroreceptor control of blood pressure in man.

Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: an Asian Multiregional, Randomized Study.

Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study

Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study

Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa

Electron beam ion sources and traps (invited)

An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer

Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naïve, metastatic castration-resistant prostate cancer

Efficacy and safety of enzalutamide (ENZ) vs placebo (PL) in chemotherapy-naïve patients (pts) with progressive metastatic castration-resistant prostate cancer (mCRPC) following androgen deprivation therapy (ADT): An Asian multinational study

Clinical Outcomes and Prognostic Factors in Nonmetastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Signaling Inhibitors Therapy

Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate

Efficacy and Safety of Abiraterone Acetate and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

Real‐world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration‐resistant prostate cancer

Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa

A study of the association between enzalutamide blood concentrations and adverse events in patients with castration-resistant prostate cancer.

Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?

Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer after Docetaxel Failure: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Bridging Study

Comparative Effectiveness of Abiraterone and Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer in Taiwan

A phase 2, randomized, open-label study comparing the effects of darolutamide versus enzalutamide monotherapy on serum testosterone levels in patients with hormone-naive prostate cancer: ARAMON study.

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide